Status and phase
Conditions
Treatments
About
This is a Phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. It includes a Phase 1 section to identify Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of IBI3001, and a Phase 2 section to explore and confirm the efficacy, safety and tolerability of IBI3001 at its RP2D.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Criteria for Phase 1 only:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
180 participants in 1 patient group
Loading...
Central trial contact
Yue Qu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal